Assessing Ketorolac (Toradol) at Oocyte Retrieval
To determine if a nonsteroidal anti-inflammatory drug (NSAID), Ketorolac (Toradol), can improve pain control and decrease narcotic use after undergoing egg retrieval.
Study InterventionsKetorolac (Toradol), Placebo (saline)Primary EndpointsAdministration of IV narcotic for rescue analgesia during recovery in the post anesthesia care unit (PACU)Study Period2022-08-10 → 2025-01 PERgoveriS In Stratified Treatment for Assisted Reproductive Technique
This is a multicenter, multi-national, randomized, open-label comparative trial. After screening, the subjects will start down-regulation treatment on Day 21-22 of the cycle. Down-regulation treatment will start within 2 months following the screening visit. The routine long luteal phase protocol for gonadotropin-releasing hormone (GnRH) agonist treatment will be followed. Once down-regulation has
Study InterventionsGonal-f®, Pergoveris®, Pergoveris®Primary EndpointsTotal Number of Oocytes RetrievedStudy Period2011-05-31 → 2012-10-31 A Phase 2 Trial to Evaluate if Corifollitropin Alfa (Org 36286), Followed by a Low Daily Dose of hCG or Recombinant FSH Can Induce Monofollicular Growth in Women With WHO Group II Anovulatory Infertility (P05693)
The primary objective of this trial is to evaluate whether a corifollitropin alfa (Org 36286) regimen applying a single or repeated dose of corifollitropin alfa followed by a low daily dose of Human Chorion Gonadotropin (hCG) or recombinant Follicular Stimulating Hormone (recFSH) can induce monofollicular growth (one follicle ≥18 mm and no other follicle ≥15 mm at day of bolus injection of hCG) in
Study Interventionscorifollitropin alfa, recombinant Follicle Stimulating Hormone (recFSH), human Chorion Gonadotropin (hCG)Primary EndpointsPercentage of Participants With Monofollicular Response (Monofollicular Rate)Study Period2007-05-15 → 2008-05-15 A Phase I Study of PepGNP-ChikV in Healthy Volunteers
This is a Phase I, randomized, single-blind, placebo-controlled, study of four separate dose cohorts, with a 42-day interval between each vaccine dose, of a novel Chikungunya Peptide Immunotherapy Vaccine in Healthy Adults (18-60 years of age).
All participants will undergo a screening visit scheduled for a maximum of 28 days before the enrolment in the clinical study and will provide a blood sam
Study InterventionsPepGNP-ChikV, PlaceboPrimary EndpointsTo assess the safety of PepGNP-ChikV candidate vaccine; To assess the reactogenicity of PepGNP-ChikV candidate vaccineStudy Period2026-08-03 → 2028-05-01 Outcomes of 36 vs 38 Hour Intervals From Ovulation Trigger To Oocyte Pick-Up:A Multi-Center Randomized Controlled Trial
Women who undergo assisted reproduction technology (ART) treatment will be eligible for this study. The goal of this randomized clinical trial is to compare the outcomes of ART treatment between women who have 36 and 38 hours interval between the administration of ovulation trigger (ovulation trigger medication initiates oocyte maturation and makes it possible for the egg to be collected by aspira
Study Interventions36-hour duration between ovulation triggering and oocyte pick-up procedure, 38-hour duration between ovulation triggering and oocyte pick-up procedurePrimary EndpointsRatio of metaphase-2 oocytes to total number of folliclesStudy Period2023-04-27 → 2025-12 IMMUNORARE5: A National Platform of 5 Academic Phase II Trials Coordinated by Lyon University Hospital to Assess the Safety and the Efficacy of the IMMUNOtherapy With Domvanalimab + Zimberelimab Combination in Patients With Advanced RARE Cancers
Immune checkpoint inhibitors (ICI) have revolutionized the management of advanced cancers. However, most rare cancers have been excluded from this progress due to the lack of clinical trials involving these diseases. After the standard first-line treatment, there are no other validated treatments for most of them. The management of these patients in ≥ 2nd line treatment relies on historic poorly e
Study InterventionsDOMVANALIMAB + ZIMBERELIMAB, DOMVANALIMAB + ZIMBERELIMAB + FOLFOX-4Primary EndpointsProgression-free survival rate (cohort 1, 3 and 5); Successful hCG normalization rate (cohort 2)Study Period2025-10-01 → 2031-06 Low Dose GnRHa Early Luteal Phase Down Regulation Versus GnRHa Ultra-short Protocol for Poor Ovarian Response
The management of the poor responder patients is very difficult. Currently, there is no any standard treatment for poor responder patients. The study is designed to test a modified GnRHa protocol for poor ovarian response, low dose GnRHa early luteal phase down regulation, compare with GnRHa ultra-short protocol. This is a randomized controlled trial.
Study InterventionsDiphereline (Triptorelin embonate), Decapeptyl (Triptorelin), human menopausal gonadotropinPrimary Endpointslive birthStudy Period2016-12 → 2020-12 The Novel Immunomodulatory and Anticoagulant Therapies for Recurrent Pregnancy Loss
In this clinical cohort study, the investigators are going to observe the efficacy of anti-coagulation and immune therapy in the treatment of recurrent pregnancy loss with a prospective randomized controlled trial.
Study InterventionsAspirin, Heparin, PrednisonePrimary Endpointslive birthStudy Period2014-10 → 2018-12-22 Type of Gonadotropin and Embryo Kinetics of Development
The study is proposed to determine the effect of three types of gonadotropins that are currently used in protocols of controlled ovarian stimulation in women undergoing in vitro fertilization techniques on the kinetics of embryonic development.
Study InterventionsCorifollitropin alfaPrimary EndpointsT5 defined as the time that embryo needs to reach a 5-cell stage.Study Period2015-04 → 2016-12 Gonadotropin Releasing Hormone Agonist (GnRHa) Versus Estrogen and Progesterone for Luteal Support in High Responders
Gonadotropin Releasing Hormone agonist (GnRHa) triggering is used as an alternative to human chorionic gonadotropin (hCG) in GnRH antagonist protocol to eliminate the risk of ovarian hyperstimulation syndrome (OHSS). However, its main disadvantage is a significantly lower pregnancy rate, hypothesized to result from a process called "luteolysis" (demise of the corpora lutea). In order to preserve a
Study InterventionsSynarel, 0.2 Mg/Inh Nasal Spray, Estrofem, UtrogestanPrimary Endpointsclinical pregnancy rate; Clinical pregnancy rate with fetal heart beatStudy Period2017-12-29 → 2021-09-30